Assistant Professor, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN
Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL.
Cleve Clin J Med. 2024 Aug 1;91(8):481-487. doi: 10.3949/ccjm.91a.24031.
is a significant public health concern given its high prevalence, growing rates of antibiotic resistance, and carcinogenic effect, all of which create management challenges for internists, gastroenterologists, and other specialty physicians. With almost half of the world's human population harboring , carcinogenic sequelae are a concern to many practitioners. Recent guidelines recommend testing high-risk populations for using noninvasive or invasive methods. eradication regimens are tailored based on the presence of effective empiric therapy (local cure rates ≥ 90% for a given regimen) or antimicrobial susceptibility testing. When empiric therapy cure rates are not optimal, guidelines recommend antimicrobial susceptibility testing to improve eradication rates and reduce the progression of antibiotic resistance.
幽门螺杆菌感染是一个重大的公共卫生问题，因为其高患病率、抗生素耐药率的不断上升以及致癌作用，这给内科医生、胃肠病学家和其他专科医生的管理带来了挑战。由于几乎全球一半的人口都携带幽门螺杆菌，致癌后果是许多医生关注的问题。最近的指南建议使用非侵入性或侵入性方法对高危人群进行幽门螺杆菌检测。根据有效经验性治疗的存在（针对特定方案的局部治愈率≥90%）或抗菌药物敏感性测试，定制幽门螺杆菌根除方案。当经验性治疗治愈率不理想时，指南建议进行抗菌药物敏感性测试，以提高根除率并降低抗生素耐药性的进展。
